DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United S…
$79.41-5.98%
报价 2026-11-06
市值
$29.62B
EV
$33.94B
PE (TTM)
34.4x
预期 PE (FY2026)
29.4x
52 周区间距高点 -14.0%
$54.84$92.34
筛选结果
pipeline · 2026-11-06Keep✗ 高增长✗ Cheap✓ GARP
GARP Pool: growth 10-30%, MC/GP <= 11
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 2.67 → 3.13（1.2x） | 25.3 |
| FY+32028-12 | 1.3x | 2.67 → 3.72（1.4x） | 21.4 |
毛利率 62% · TTM 收入 $5104M · 基数 EPS 2.67（调整后）
电话会信号
辅助标签Q3 20262026-10-29
扩产上调指引
指引 上调
信心 4
分析师 4
“We are updating our revenue guidance to be in the range of $5.20 billion to $5.25 billion, representing growth of 12% to 13% for the year.”
原文引用（2）
- 扩产：Ireland expands our manufacturing capacity and strengthens the resilience of our global supply network.
- 上调指引：We are updating our revenue guidance to be in the range of $5.20 billion to $5.25 billion, representing growth of 12% to 13% for the year.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| DXCMDexCom, Inc. | $29.62B | -6.0% | +12.4% | 63.4% | 34.4x | 21.8x | 23.9x | GARP |
| TEVATeva Pharmaceutical Industries Limited | $49.65B | +2.0% | -0.7% | 55.5% | 93.0x | 30.3x | 39.5x | |
| WATWaters Corporation | $44.93B | +1.0% | +103.6% | 58.9% | 28.0x | 18.3x | 83.3x | 高增长 |
| BIIBBiogen Inc. | $36.71B | +1.8% | +0.6% | 70.5% | 20.8x | 10.0x | 17.2x | |
| LHLabcorp Holdings Inc. | $29.77B | +0.9% | +5.9% | 29.8% | 27.6x | 15.9x | 23.9x | |
| PHGKoninklijke Philips N.V. | $29.66B | -0.5% | – | 45.2% | 24.5x | 10.1x | – | |
| WSTWest Pharmaceutical Services, Inc. | $27.85B | +1.9% | +11.6% | 39.7% | 45.5x | 29.2x | 62.7x | |
| STESTERIS plc | $24.6B | -0.7% | +7.3% | 44.7% | 29.9x | 17.0x | 26.3x | |
| ZBHZimmer Biomet Holdings, Inc. | $20.14B | -1.2% | +4.7% | 71.2% | 26.6x | 11.9x | 12.2x | |
| 同行中位数 | – | – | +5.9% | 50.3% | 27.8x | 16.4x | 26.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
上次生成失败：API错误: Error code: 402 - {'error': {'message': 'Insufficient Balance', 'type': 'unknown_error', 'param': None, 'code': 'invalid_request_error'}}
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31B | $1.19B | $1.26B | $1.21B | $1.16B | $1.04B | $1.11B | $994.2M |
| Gross Margin | 63.4% | 62.9% | 62.9% | 60.5% | 59.5% | 56.9% | 58.9% | 59.7% |
| Operating Margin | 24.3% | 21.4% | 25.6% | 20.1% | 18.4% | 12.9% | 17% | 15.3% |
| Net Income | $249.1M | $199.5M | $267.3M | $283.8M | $179.8M | $105.4M | $151.7M | $134.6M |
| Diluted EPS | 0.64 | 0.51 | 0.68 | 0.7 | 0.45 | 0.27 | 0.38 | 0.34 |
| Operating Cash Flow | $269.2M | $525.6M | $294M | $659.9M | $303M | $183.8M | $301.4M | $199.5M |
研究材料
Filing 摘要